Revenues

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Revenues

Revenues

We operate our business in one operating segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW product sales relates to products sold in Europe.

Revenues were as follows (in millions):

	Three months ended March 31,
	2025						2024
	U.S.		ROW		Total		U.S.		ROW		Total
Prolia	$	720	$	379	$	1,099	$	657	$	342	$	999
Repatha	343		313		656		273		244		517
XGEVA	360		206		566		366		195		561
ENBREL	504		6		510		561		6		567
EVENITY	320		122		442		236		106		342
Otezla	343		94		437		293		101		394
TEPEZZA	365		16		381		419		5		424
BLINCYTO	273		97		370		153		91		244
Aranesp	91		249		340		100		249		349
KYPROLIS	216		108		324		234		142		376
Nplate	201		112		313		190		127		317
TEZSPIRE(1)	285		—		285		173		—		173
Vectibix	135		132		267		120		127		247
KRYSTEXXA	236		—		236		235		—		235
Other products(2)	1,270		377		1,647		963		410		1,373
Total product sales(3)	$	5,662	$	2,211	7,873		$	4,973	$	2,145	7,118
Other revenues					276						329
Total revenues					$	8,149					$	7,447

_______

(1)    TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.

(2)    Consists of product sales of our non-principal products.

(3)    Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2025 and 2024.